Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future.

Introduction: There has been a paradigm shift in the treatment of chronic lymphocytic leukemia (CLL) over the past decade. With the advent of self-administered targeted oral anticancer agents (OAAs), the treatment of CLL has begun to shift from the infusion clinic to the patient's home. This introduced new challenges including patient non-adherence, class-specific adverse effects, and financial toxicity to treatment.

The Presence 5 for Racial Justice Framework for anti-racist communication with Black patients.

Objective: To identify communication practices that clinicians can use to address racism faced by Black patients, build trusting relationships, and empower Black individuals in clinical care.

Data Sources: Qualitative data (N = 112 participants, August 2020-March 2021) collected in partnership with clinics primarily serving Black patients in Leeds, AL; Memphis, TN; Oakland, CA; and Rochester, NY.

Study Design: This multi-phased project was informed by human-centered design thinking and community-based participatory research principles.

Meeting Behind the Seen: Synchronous Teaching without Virtual Meeting Fatigue.

Videoconferencing platforms provide opportunities for synchronous teaching and interaction between classmates but they come with disadvantages including video fatigue. Moreover, presenters using videoconferencing programs may feel as if they are lecturing into a void. In an online class on Behavioral Pharmacology, we used Google Meet essentially as a conference call in the background while the class "met" within a Google Doc that everyone could edit.

Hereditary Coproporphyria Mimicking Guillain-Barré Syndrome After COVID-19 Infection.

Hereditary coproporphyria (HCP) is a rare disorder caused by a deficiency of an enzyme, coproporphyrinogen oxidase, in the heme synthetic pathway. This disease has a highly variable clinical presentation with acute attacks of neurologic symptoms that can last from days to months. Rarely, it and other acute porphyrias may cause ascending paralysis, which is difficult to distinguish from Guillain-Barré syndrome (GBS).